Patents by Inventor Neil L. Spector

Neil L. Spector has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220226666
    Abstract: A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body; infusing the diseased site with a photoactivatable drug; applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume, wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 21, 2022
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, JR., Harold Walder, Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
  • Patent number: 11305131
    Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: April 19, 2022
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, Jr., Harold Walder, Mark DeWhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
  • Publication number: 20200009398
    Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
    Type: Application
    Filed: August 29, 2019
    Publication date: January 9, 2020
    Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Frederic A. BOURKE, JR., Harold WALDER, Mark DEWHIRST, Neil L. SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA
  • Patent number: 10441810
    Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 15, 2019
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Harold Walder, Frederic A. Bourke, Jr., Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
  • Publication number: 20170157418
    Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
    Type: Application
    Filed: February 16, 2017
    Publication date: June 8, 2017
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Harold WALDER, Frederic A. BOURKE, JR., Mark DEWHIRST, Neil L. SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA
  • Publication number: 20160331731
    Abstract: Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.
    Type: Application
    Filed: July 27, 2016
    Publication date: November 17, 2016
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Wenle XIA, David Gooden, Erik J. Soderblom, Eric J. Toone, Neil L. Spector, Wayne F. Beyer, JR., Harold Walder
  • Patent number: 9439897
    Abstract: Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: September 13, 2016
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Wenle Xia, David Gooden, Erik J. Soderblom, Eric J. Toone, Neil L. Spector, Wayne F. Beyer, Jr., Harold Walder
  • Publication number: 20150202294
    Abstract: Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.
    Type: Application
    Filed: January 23, 2015
    Publication date: July 23, 2015
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Wenle XIA, David GOODEN, Erik J. SODERBLOM, Eric J. TOONE, Neil L. SPECTOR, Wayne F. BEYER, JR., Harold WALDER
  • Publication number: 20100063074
    Abstract: The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and pharmaceutical compositions containing the same. In particular, the method relates to a methods of treating cancers which are mediated by the tyrosine kinases EGFR and/or erbB2 by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof.
    Type: Application
    Filed: June 1, 2005
    Publication date: March 11, 2010
    Inventors: Mark S. Berger, Tona Morgan Gilmer, Arundathy Nirmalini Pandite, David Rusnak, Neil L. Spector, Iman El-Hariry
  • Patent number: 6277844
    Abstract: The invention provides compounds of the formula (I): wherein R1 is an amino or an alkyl group, optionally substituted with one or more groups selected from C1-C6 alkyl group; R2 is H or halogen; R3 is H, halogen, hydroxyl group, or alkyl group; R4 is H or halogen; and R5 is halogen, preferably chlorine; and salts and prodrugs thereof; and a method of using these compounds for the treatment of cancer.
    Type: Grant
    Filed: September 14, 1999
    Date of Patent: August 21, 2001
    Inventors: Sydney Spector, Neil L. Spector